Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bisoprolol-Amlodipine FDC vs Separate Tablets in Healthy Chinese Subjects
NCT03226275Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bisoprolol + amlodipine in hypertension (HTN) (4 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time at Day 15 and Maximum Observed Plasma Concentration at Day 15. Started Aug 2017; status: completed.
02
Drugs
bisoprolol + amlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03226275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226275.